参考文献/References:
[1] 中华医学会糖尿病学分会 中国2型糖尿病防治指南(2017年版)[J].中国实用内科杂志,2018,38(4):292-344.
[2] 高斯德,李卫萍,李虹伟.钠-葡萄糖协同转运蛋白抑制剂与心力衰竭的研究进展[J].心血管病学进展,2018,39(5):703-708.
[3] Zinman B.Wanner C,Lachin JM,et al.Empagliflozin,cardiovascular outcomes,and mortality in type 2 diabetes[J]. N Engl J Med,2015,373(22):2117-2128.
[4] Grant PJ,Cosentino F. The 2019 ESC Guidelines on diabetes,pre-diabetes,and cardiovascular diseases developed in collaboration with the EASD:new features and the ‘Ten Commandments’ of the 2019 Guidelines are discussed by Professor Peter J.Grant and Professor Francesco Cosentino,the Task Force chairmen[J]. Eur Heart J,2019,40(39):3215-3217.
[5] Mahaffey KW,Neal B,Perkovic V,et al.Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS Program(Canagliflozin Cardiovascular
Assessment Study)[J]. Circulation,2018,137(4):323-334.
[6] Wiviott SD,Raz I,Bonaca MP,et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med,2019,380(4):347-357.
[7] Karg MV,Bosch A,Kannenkeril D,et al. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content:a randomised controlled trial[J]. Cardiovasc Diabetol,2018,17(1):5.
[8] Hallow KM,Helmlinger G,Greasley PJ,et al.Why do SGLT2 inhibitors reduce heart failure
hospitalization?A differential volume regulation hypothesis[J].Diabetes Obes Metab,
2018,20(3):479-487.
[9] Baker WL,Smyth LR,Riche DM,et al. Effects of sodium glucose co-transporter 2 inhibitors on blood pressure:a systematic review and meta-analysis[J].J Am Soc Hypertens,2014,8(4):262-275.
[10] Perkins BA,Udell JA,Cherney DZI. No need to sugarcoat the message:is cardiovascular
risk reduction f rom SGLT2 inhibition related to natriuresis?[J].Am J Kidney Dis,2016,68(3):349-352.
[11] Townsend RR,Machin I,Ren J,et al. Reductions in mean 24-hour ambulatory blood pressure after 6-week treatment with canagliflozin in patients with type 2 diabetes mellitus and hypertension[J].J Clin Hypertens(Greenwich),2016,18(1):43-52.
[12] Li HL,Shin SE,Seo MS,et al.The anti-diabetic drug dapagliflozin induces vasodilation via activation of PKG and Kv channels[J]. Life Sci,2018,197:46-55.
[13] Solini A,Giannini L,Seghieri M,et al. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients:a pilot study[J]. Cardiovasc Diabetol,2017,16(1):138.
[14] Santos-Gallego CG,Requena-Ibanez JA,San Antonio R,et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics[J]. J Am Coll Cardiol,2019,73(15):1931-1944.
[15] Yurista SR,Silljé HHW,Oberdorf-Maass SU,et al. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction[J]. Eur J Heart Fail,2019,21(7):862-873.
[16] Kappel BA,Lehrke M,Schütt K,et al. Effect of empagliflozin on the metabolic signature of
patients with type 2 diabetes mellitus and cardiovascular disease[J].Circulation,2017,136(10):969-972.
[17] Baartscheer A,Schumacher CA,Wüst RCI,et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na +/H+ exchanger in rats and rabbits [J].Diabetologia,2017,60(3):568-573.
[18] Uthman L,Baartscheer A,Bleijlevens B,et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts:inhibition of Na+/H+?exchanger,lowering of cytosolic Na+?and vasodilation[J]. Diabetologia,2018,61(3):722-726.
[19] Packer M,Anker SD,Butler J,et al. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure:proposal of a novel mechanism of action[J]. JAMA Cardiol,2017,2(9):1025-1029.
[20] Fedak PW,Ver ma S,Weisel RD,et al. Cardiac remodeling and failure from molecules to man (part Ⅱ)[J]. Cardiovasc Pathol ,2005,14(2):49-60.
[21] Lee TM,Chang NC,Lin SZ.Dapagliflozin,a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts[J]. Free Radic Biol Med ,2017,104:298-310.
[22] Kang S,Verma S,Hassanabad AF,et al. Direct effects of empagliflozin on extracellular matrix remodelling in human cardiac myofibroblasts:novel translational clues to explain EMPA-REG OUTCOME results[J]. Can J Cardiol,2020,36(4):543-553.
[23] Shi L,Zhu D,Wang S,et al. Dapagliflozin attenuates cardiac remodeling in mice model of cardiac pressure overload[J]. Am J Hypertens,2019,32(5):452-459.
[24] Packer M. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin?A novel hypothesis[J]. Diabetes Obes Metab,2018,20(6):1361-1366.
[25] Garvey WT,van Gaal L,Leiter LA,et al . Effects of canagliflozin versus glimepiride on adipokines a nd inflammatory biomarkers in type 2 diabetes[J].Metabolism,2018,85:32-37.
[26] Sato T,Aizawa Y,Yuasa S,et al. The effect of dapagliflozin treatment on epicardial adipose tissue volume[J].Cardiovasc Diabetol,2018,17(1):6.
相似文献/References:
[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(9):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(9):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[3]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(9):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[4]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(9):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[5]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(9):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[6]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(9):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[7]渠海贤 李涛 程流泉.人工智能在心脏磁共振成像中的应用进展[J].心血管病学进展,2019,(5):659.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.001]
[8]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(9):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[9]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(9):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
[10]韦莹 刘书旺 李蕾 崔鸣.生长分化因子-15在心房颤动中的研究进展[J].心血管病学进展,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
WEI Ying,LIU Shuwang,LI Lei,et al.Growth Differentiation Factor-15 in Development of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(9):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
[11]李嘉仪 黄龙祥 罗素新.钠-葡萄糖协同转运蛋白-2抑制剂在心血管疾病中的研究进展[J].心血管病学进展,2019,(9):1245.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.015]
LI JiayiHUANG LongxiangLUO Suxin.SGLT-2 Inhibitors in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(9):1245.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.015]
[12]耿肖囡 肖东斌 魏鑫 惠学志.达格列净对心血管疾病的预防保护机制[J].心血管病学进展,2019,(8):1169.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.025]
GENG Xiaonan,XIAO Dongbin,WEI xin,et al.Preventive and Protective Mechanism of Dagliflozin for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(9):1169.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.025]
[13]辛玉晶,刘昊凌.钠-葡萄糖协同转运蛋白２抑制剂与2型糖尿病心血管危险因素的研究进展[J].心血管病学进展,2020,(3):235.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.005]
XIN Yujing,LIU Haoling.SGLT-2 Inhibitors and Cardiovascular Risk Factors in Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2020,(9):235.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.005]
[14]王景如 刘素云.改善2型糖尿病患者的不良心血管结局：GLP-1RA与SGLT-2i可联合应用吗？[J].心血管病学进展,2022,(8):739.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.018]
WANG Jingru,LIU suyun.Improve Adverse Cardiovascular Outcomes in Patients with Type 2 DiabetesCan GLP-1RA be Combined with SGLT-2i[J].Advances in Cardiovascular Diseases,2022,(9):739.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.018]
[15]王歆烨,崔萌萌,赵刚,等.司美格鲁肽治疗2型糖尿病心血管并发症的研究进展[J].心血管病学进展,2023,(8):733.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.014]
WANG Xinye,CUI Mengmeng,ZHAO Gang,et al.Treatment with Semaglutide in Cardiovascular Complications of?ype 2 Diabetes[J].Advances in Cardiovascular Diseases,2023,(9):733.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.014]